Collegium Pharmaceutical nabywa AZSTARYS od Corium Therapeutics

Collegium Pharmaceutical will maintain or improve gross margin on AZSTARYS at 70% or higher within 24 months post-acquisition, indicating effective cost management and pricing power in the ADHD medication market.

AZSTARYS will generate at least $180 million in incremental annual revenues for Collegium Pharmaceutical within 18 months post-acquisition close, representing successful integration and commercial performance justifying the $650 million acquisition price.

Collegium Pharmaceutical's debt-to-EBITDA ratio will not exceed 3.5x within 12 months post-acquisition close, demonstrating manageable leverage and financial stability despite the $650 million acquisition financing.

AZSTARYS will capture at least 12% of new ADHD medication prescriptions written in the United States within 24 months post-acquisition close, demonstrating successful market penetration and competitive displacement of alternative treatments.

Collegium Pharmaceutical will maintain R&D spending as a percentage of revenue within 8-12% of pre-acquisition levels in the first fiscal year post-close, indicating preserved innovation investment capacity despite acquisition financing burden.

Collegium Pharmaceutical's stock price will outperform the S&P 500 Healthcare Index (XLV) by at least 8% within 90 days post-acquisition announcement, reflecting positive market sentiment toward the AZSTARYS acquisition strategic fit and revenue diversification.

Collegium Pharmaceutical's operating cash flow will decline by no more than 12% in the first fiscal year post-acquisition compared to the prior year, indicating successful cash management despite $650 million acquisition financing and integration expenses.

AZSTARYS will achieve at least 15% year-over-year market share growth in the ADHD medication segment within 18 months post-acquisition, indicating successful commercial execution and competitive positioning against existing treatments.

Collegium Pharmaceutical's debt-to-equity ratio will increase by no more than 0.15 points within 12 months post-acquisition, demonstrating manageable leverage from the $650 million+ acquisition financing despite integration costs.

Collegium Pharmaceutical's gross margin will remain stable or improve (within -2% to +3% range) in the first two quarters post-acquisition despite integration costs, indicating successful operational synergy management.

AZSTARYS will contribute at least $85 million in net revenue to Collegium Pharmaceutical in the first full fiscal year (12 months) post-acquisition, representing successful market penetration in the competitive ADHD medication segment.

Collegium Pharmaceutical (COLL) stock price will increase by at least 8% within 30 days following the AZSTARYS acquisition announcement due to positive market sentiment regarding the addition of a commercial-stage ADHD treatment to the product portfolio.